@FierceBiotech: Eisai wins an early FDA nod for its self-described cancer blockbuster. Report | Follow @FierceBiotech
@JohnCFierce: Biotech boom drives blockbuster VC investments in Boston, San Francisco. Story | Follow @JohnCFierce
@DamianFierce: Eisai exec told WSJ yesterday that lenvatinib approval was "imminent." Well. FDA announcement | Follow @DamianFierce
> The FDA has accepted Pfizer's ($PFE) application for ALO-02, an abuse-deterrent painkiller that combines oxycodone and naltrexone. The company didn't disclose when it expects to get a final ruling from the agency. More
> A generation of Chinese scientists who once left the country for jobs in western pharma are returning home, lured by the nascent biotech ecosystem there, Reuters reports. Story
Medical Device News
@FierceMedDev: J&J joins forces with JDRF for type 1 diabetes Dx. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: NIH discusses 'precision medicine' genomics initiative and how to build a million-person research cohort. Item | Follow @VarunSaxena2
@EmilyWFierce: Better training for pediatricians could help increase use of IUDs in teenage girls. Story from The Atlantic | Follow @EmilyWFierce
> USAID backs wearable tech initiative for Ebola from Scripps. Article
> Disposable insulin device maker Valeritas files to raise up to $90M in an IPO. Report
Pharma News
@FiercePharma: UPDATED: Valeant, Shire prep Salix bids. Article | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere. Report | Follow @CarlyHFierce
> Activists ready to fight for Ariad CEO's ouster: CNBC. More
> Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU. Article
> England's price watchdog writes off Celgene's Imnovid in final guidance. Story